Gameto | Redefining women's health

Engineering the future of reproductive health.

Despite a growing infertility crisis, reproductive health has received limited focus and investment. Gameto is working on groundbreaking solutions that put women and families first.

First Baby Born Using iPSC Technology

Gameto's iPSC-derived technology is designed to dramatically improve IVF and is showing promise in clinical studies.

Fertilo has not been approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy.

Cell Therapy to Help with Menopause

Despite the fact that over 1 billion women will experience menopause by 2025, few effective treatments exist.

With the help of our recent funding award through ARPA-H's Sprint for Women's Health Initiative, we believe our proprietary cell engineering will help delay the unwanted effects of menopause.

Forbes

"Next Generation IVF Startup"

Gameto, co-founded by Under 30 alumna Dina Radenkovic, has serious potential. Now it’s finally coming to market.

Endpoints News

"Gameto Cleared by FDA to Test Easier IVF Process"

Gameto has received permission from the FDA to investigate whether our ovary-in-a-dish technology can make IVF a less grueling process.

From egg freezing and IVF, to ovarian disease and menopause

Gameto is a first-of-its-kind biotechnology company on a mission to address significant unmet needs for women and families throughout their reproductive years — and beyond.

Transforming reproductive health using modern science

Gameto’s groundbreaking cell engineering platform has the potential to solve many of the problems at the heart of the global infertility crisis.

The first application of our technology, Fertilo, aims to improve the current IVF and egg freezing landscape using engineered ovarian support cells.

Fertilo

Our lead program. Improving outcomes for IVF and other fertility methods.

Deovo

Testing and developing drugs for ovarian disease.

Ameno

Making the medical burden of menopause optional.

WHAT IS FERTILO ?

IVF and Egg Freezing, Simplified

Fertilo enables egg maturation outside the body. It is designed to make IVF and egg freezing shorter, easier, and more accessible for patients everywhere. It uses engineered ovarian cells to replicate your body’s natural maturation. In the U.S., it is an investigational biologic currently advancing through a Phase 3 clinical trial, in which it will be evaluated for safety and efficacy. It is not approved for marketing in the US.

STAGE 1

Immature Eggs Retrieved

Collected after 1–3 days of minimal hormone stimulation.

STAGE 2

Fertilo Maturation Ex Vivo

Engineered cells nurture eggs in the lab for about 24 hours.

STAGE 3

Mature Eggs Ready

Fertilized or frozen within 2–6 hours after maturation, just like conventional IVF.

ACCESS FERTILO

A Better IVF Experience, Designed for You

Fertilo offers a shorter, easier approach to IVF and egg freezing. Whether you are exploring your options, interested in the U.S. clinical trial, or ready to find a clinic outside the U.S., we are here to support you.

Clinical Trials

Join our no-cost clinical trials for advanced care.

Fertilo Clinics

See where Fertilo is available worldwide.

Because women and families deserve more.

Infertility impacts 1 in 6 people worldwide, including our own friends, family, and colleagues. This fight is personal for us, because it’s personal for everyone.

We believe everyone deserves access to solutions that give them the best chance at achieving their family planning goals and dreams.